Randomised phase III trial comparing irinotecan plus capecitabine (XELIRI Regimen) vs. irinotecan, 5-Fu and folinic acid (Saltz regimen) as first-line treatment in patients (PTS) with metastatic colorectal cancer (MCRC)
ANNALS OF ONCOLOGY（2006）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要